FOR IMMEDIATE RELEASE: Rapid Drug Screen Will Be Used to Test 250,000 Dominican Applicants for Gun Permits KINDERHOOK, NY -- May 30, 2024 -- American Bio Medica Corporation (NASDAQ: ABMC) today announced that it and its distributor partner, Vanter S.A., had been awarded a broad-scale, two-year drug testing contract by the government of the Dominican Republic. Under the agreement, ABMC's Rapid Drug Screen will be used to drug test all private citizens of the Dominican Republic who apply for weapons permits. The progressive program is administered by the Secretary of the Dominican Republic to ensure that guns are not in the hands of individuals with chronic drug abuse problems. As many as 250,000 applicants are tested each year in order to obtain or renew permits. "This is an important contract because it involves high volume of product, and it represents a further strengthening of ABMC's international presence and distributor involvement," noted ABMC chief executive officer Robert L. Aromando, Jr. "It also underscores the flexibility and reliability of Rapid Drug Screen as an anti-crime tool. The program will be able to handle as many as 1,000 or more registrations per day, involving drug tests throughout the country." The program will commence in June. Under the agreement, ABMC will provide on-site drug tests to Vanter, which will then be responsible for test distribution and personnel training within the Dominican Republic. About American Bio Medica Corporation American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate, on-site drugs-of-abuse diagnostic kits, sprays and support services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical, and educational markets. In addition to Drug Detector, ABMC markets Rapid Drug Screen, which is designed to test individuals and is proven to correlate greater than 99% with the standard laboratory screening test. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. Contact: American Bio Medica Corporation, Kinderhook Melissa A. Decker Tel: 800/227-1243 Fax: 518/758-8171 www.americanbiomedica.com melissa@americanbiomedica.com |